Brochure | Renal function | Kidney health| Nephrology | Kidney disease

Finerenone Shows Promise in Heart Failure and Kidney Disease Management

2025-04-01 - 2025-04

John Ostrominski, MD: So, there have been several analyses and several trials that have evaluated the treatment effects of finerenone in persons first with actually type 2 diabetes [T2D] and chronic kidney disease [CKD], and then more recently, in persons with [HF] with an ejection fraction of 40 or 40% or higher. And the primary results of the trial essentially showed a 20% reduction on the primary composite end point of cardiovascular death and total worsening [HF] events.

And that's the overall efficacy piece. And then the safety piece—there have been prior experiences with similar agents in the class, mineralocorticoid receptor antagonists [MRA]. And the one prior trial, called TOPCAT [NCT00094302], evaluated spironolactone [Aldactone; Pfizer Medical] which varies a little bit in terms of its actual— in terms of its mechanism of action compared with finerenone. And—but there were well-recognized higher incidences of increased potassium levels, but also lower risks of lower potassium levels. And finerenone, overall, within FINEARTS-HF, was very well tolerated. And there were slight increases in hyperkalemia and also lower risks of hypokalemia. And there were also slight increases in serum creatinine levels, but overall, the profile was very well tolerated.

Webinar on Renal function

Brochure Form

useful links

Latest News

Finerenone Shows Promise in Heart Failure and Kidney Disease Management

renalfunction@confmeets.net

support@confmeets.net

+44 789 707 2181